Endo risk/reward remains favorable, says Citi. After hosting management on a roadshow, Citi analyst Liav Abraham says the risk/reward on shares of Endo International remains favorable. The analyst views the current valuation as “undemanding” and believes “solid execution” of the base business creates upside to Street estimates. She keeps a Buy rating on Endo shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.